Can freezing tumors offer a new lifeline for head and neck cancer?

NCT ID NCT05738187

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 20, 2026 · Last updated Aug 21, 2026 · Updated 1 time

Summary

This pilot study is investigating whether local cryotherapy—a procedure that freezes and destroys cancer cells—can control recurrent head and neck cancer in patients who have already received radiation therapy and cannot undergo surgery or further radiation. The trial will enroll 15 adults with unresectable, recurrent tumors in previously irradiated areas. The main goal is to see if cryotherapy can stop tumor growth without causing severe side effects, potentially offering a safer alternative to re-irradiation.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
local cryotherapy treatment (a procedure that freezes and destroys cancer cells)
What this could lead to
If effective, cryotherapy could offer a new, less toxic treatment option for people with recurrent head and neck cancer who cannot have surgery or re-irradiation, potentially improving local control and survival.
What could go wrong
This is a small pilot study, so results may not be conclusive. Cryotherapy may not fully control the tumor, and there is a risk of complications or side effects, including damage to nearby tissues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 15 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2024

Expected to finish

May 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Malignant head/neck tumor * Unresectable locoregional recurrence in a previously irradiated area * Contraindication to re-irradiation * Age \> 18 years * Performance index ≤ 2 (WHO) * Life expectancy \> 12 weeks * Absence of hemostasis disorders * Renal function: creatinine clearance ≥ 30 mL/min by CKD-EPI method (Cockcroft-Gault formula or MDRD) * Subject affiliated to a social security health insurance plan * Subject able to understand the objectives and risks of the research and to give dated and signed informed consent * For a woman of childbearing age, negative blood pregnancy test at the inclusion visit Exclusion Criteria: * Stage IV with distant metastases or multiple tumors * Melanoma, sarcoma, and lymphoma * Participants who have received chemotherapy or radiation therapy within 4 weeks * Other active cancer within the past 2 years (patients with carcinoma in situ, papillary thyroid carcinoma, basal cell skin carcinoma, localized Gleason 6 prostate cancer, or breast cancer in situ are allowed) * Concomitant therapy with any other systemic anticancer treatment * Contraindication of anaesthesiology character * Contraindication to MRI * Participation in another clinical study * Any social, medical or psychological condition that may prevent the patient from complying with the constraints of the protocol * Any significant pathology that may interfere with the patient's participation in the study * Subject under court protection * Subject under guardianship or curatorship * Pregnant or breastfeeding women

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Local cryotherapy treatment are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck cancer Head and Neck Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hôpitaux Universitaires de Strasbourg

    RECRUITING

    Strasbourg, 67000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.